

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A, Rule 17.06B and 17.06C of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) has granted an aggregate of 1,315,322 share options (the “**Share Option(s)**”) under the share scheme adopted by the Company on 19 June 2023 (the “**Share Scheme**”) to two eligible participants (the “**Grantees**”), who is one employee (the “**Employee Participant**”) and one service provider (the “**Service Provider Participant**”), subject to the acceptance of the Share Options by the Grantees, to subscribe for up to an aggregate of 1,315,322 ordinary shares of the Company (the “**Shares**”) of US\$0.00001 each, representing approximately 0.07% of the issued share capital of the Company as at the date of this announcement.

Details of the Share Options granted

Date of grant	: 12 September 2023
Number of the Share Options granted	: An aggregate of 1,315,322 Share Options, each Share Option entitling the holder to subscribe for one Share at the exercise price
Exercise price of the Share Options granted	: HK\$12.88 per Share
Closing price of the Shares on the date of grant	: HK\$12.80 per Share

- The average closing price of the Shares for the five trading days immediately preceding the date of grant : HK\$12.88 per Share
- Validity period of the Share Options : Ten (10) years from the date of grant, i.e. from 12 September 2023 to 11 September 2033
- Consideration for the grant : US\$1.00 to be paid by the Grantees upon acceptance of the Share Options granted
- Performance target : There is no performance target attached to the Share Options granted.
- The purpose of the Share Scheme is to provide incentive to the eligible participants in order to promote the development and success of the business of the Group. The number of Share Options to be granted are based on the work performance and potential contributions of the Grantees and no additional performance target is imposed before the Share Options are vested to the Grantees. In view of the above, the remuneration committee of the Company considered the grant of Share Options aligned with the purpose of the Share Scheme.
- Clawback mechanism : The Share Options granted were subject to the clawback mechanism as set out in the terms of the Share Scheme, including but not limited to the lapse of the Share Options upon cessation of employment of the Grantees and the cancellation of Share Options at the discretion of the Board.
- Financial assistance : There is no arrangement for the Group to provide any financial assistance to the Grantees to facilitate the purchase of Shares under the Share Scheme.

Details of the Grantees

Class of Grantees	Number of Share Options Granted	Approximate percentage of the issued share capital of the Company
Employee Participant	200,000	0.01%
Service Provider Participant	<u>1,115,322</u>	<u>0.06%</u>
	Total	0.07%
	<u>1,315,322</u>	<u>0.07%</u>

Vesting conditions

Employee Participant 40,000 Share Options shall vest on the first anniversary of the date of grant, and an additional 40,000 Share Options shall vest on each of the second anniversary, the third anniversary, the fourth anniversary and the fifth anniversary of the date of grant.

Service Provider Participant

- (1) 115,322 Share Options granted shall vest and become exercisable on the fifth anniversary of the grant date; and
- (2) 200,000 Share Options shall vest on the first anniversary of the date of grant, and an additional 200,000 Share Options shall vest on each of the second anniversary, the third anniversary, the fourth anniversary and the fifth anniversary of the date of grant.

Service Provider Participant

The purpose of the Share Scheme is to provide incentive to the eligible participant in order to promote the development and success of the business of the Group. The Share Scheme will give the eligible participant an opportunity to have a personal stake in the Company and will help motivate the eligible participant in optimising their performance and efficiency and attract and retain the eligible participant whose contributions are important to the long-term growth of the Group.

The Company is a leading medical device group focusing on innovating, manufacturing and marketing high-end medical devices globally.

The Service Provider Participant provides consulting services to the Company. Given that the services being provided by the Service Provider Participant are in areas that are desirable and necessary from a commercial or strategic perspective of the Group and help maintain or enhance the competitiveness of the Group, the Board believes that the grant of the Share Options to the Service Provider Participant can align its interests with the interests of the Company and the shareholders of the Company, motivate the Service Provider Participant to commit to the Company's future continued competitiveness, operating results and growth, and strengthen its long-term service commitment to the Company, and therefore serves the purposes of the Share Scheme.

NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT

After the above grant of Share Options, 182,031,183 remaining Shares will be available for future grant under the existing scheme mandate limit of the Share Scheme, and 35,553,979 remaining Shares will be available for future grant under the service provider sublimit under the Share Scheme.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the People's Republic of China, 12 September 2023

As at the date of this notice, the executive director is Dr. Zhaohua Chang; the non-executive directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Ms. Weiqin Sun and Dr. Qiyi Luo; and the independent non-executive directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*